Finch Therapeutics Group (FNCH)
(Delayed Data from OTC)
$1.33 USD
-0.02 (-1.48%)
Updated Jun 7, 2024 01:22 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FNCH 1.33 -0.02(-1.48%)
Will FNCH be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for FNCH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FNCH
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings Estimates
FNCH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why
Other News for FNCH
SCWorx, Cue Health, Sensei Biotherapeutics among healthcare movers
Seth Klarman's Baupost cuts Warner Bros. stake, takes in SoundHound, among others
FNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q1 2024
CSSE, RVYL and RCAT among mid-day movers
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers